Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma

NCT00116597 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT00116597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00116597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2002
Completion date
December 31, 2008
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma